Collagen type II STUDY RESULTS
Harvard University School of Medicine
by Alex Duarte, O.D., Ph.D.
At Harvard University School of Medicine, Dr. David Trentham and
his colleagues gave very small doses of solubilized collagen type
II to 10 patients with rheumatoid arthritis. These patients had
all immunosuppressive drugs and anti-inflammatories such as methotrexate
and mercaptopurine removed before they took the collagen type
II.
Patients took small doses of collagen type II for one month and
then increased the dosage for two months thereafter. The dosage
was determined through the various animal studies that had determined
specific concentrations.
The clinical response was defined as a 50% or greater improvement
in the number of swollen and tender joints, accompanied by a 50%
or greater improvement in two additional measures (morning stiffness,
15 meter walking time, grip strength, Westergren erythrocyte sedimentation
rate, or physician global assessment), lasting for at least two
months after the treatment period.
SIXTY PERCENT of the patients showed
substantial clinical response and one patient showed a complete
response in which the disease was totally eliminated for 26 months.
More importantly, there were absolutely no side effects.
These results were so profound that a 90 day, double blind, phase
two study was conducted on 60 patients with very severe, active
rheumatoid arthritis. It's important to note that these patients
were not beginning or moderate cases, but the most severe cases
that can be usually encountered.
Patients either received the solubilized type II collagen or
a placebo. (A placebo is a non-active type II
collagen look-alike). The concentration was equivalent to that
in the first study.
At the end of the study, 59 of the 60 patients were evaluated.
Twenty-eight had received the collagen type II and 31 had received
the placebo.
Compared to the placebo group,
the collagen type II group showed significant improvements in
joint swelling, tenderness or pain. This also
included the degree of swelling and tenderness together. The doctors
evaluated the response in a 15 meter walking time at months one,
two and three. During the period at which the patients were taken
off immunosuppressant drugs, those that received the collagen
type II show stability and/or even improvement while those in
the placebo group tended to deteriorate. However, four of the
patients in the placebo group did show a significant placebo effect.
Four patients in the collagen type
II group went into the next realm of the almost unbelievable,
and showed a complete resolution of the disease.
That is correct. You have read this material correctly. These
people no longer had symptoms of rheumatoid arthritis. It must
be understood that no patients in the placebo group showed remission.
No side effects or negative laboratory effects were seen during
the study.
It is believed that by feeding type II soluble collagen to rheumatoid
arthritis patients, their T-cell function is modulated either to the
extent that the suppressor T-cells are triggered and migrate to the
joint to block the T-cell mediated inflammation, or it just simply
stops the T-cell destruction of the joint.
The Harvard Study was sponsored by Autoimmune, a Lexington, Massachusetts
biotechnology company. Only highly purified chicken sternal collagen
type II was used.
This report from the book entitled "The Collagen Type
II Cure for Arthritis and Heart Disease", by Alex Duarte, O.D.,
Ph.D. Published October 1997, ISBN # 1-891036-11-4

The total without a response of less pain in forty-five
days was three or appox. 10.1% and only one placebo subject recorded
a response in forty-five days.
Side effects - Only one subject had nausea. It was
noted that he was on other medications as well.
CONCLUSION
Collagen Type II treatment had a significant effect
on subjective pain syndromes. Most subjects responded to Collagen
Type II in the first 21 days of the trial. Many of these pained
subjects had previously been on long-term, pharmaceutical treatment
programs. Many subjects responded by initiating life style changes
due to lack of pain. Many were excited by the increase in their
daily activity. The results have prompted the authors to develop
specific disease/pain syndrome trials in the near future.
AUTHORS
Drs. K. Buckman; J. Gutierrez; et. al
FROM Bill Phillips Supplement
Review
Over the past few years, scientists have been exploring
the possibility that supplementing Collagen Type II may actually
help arthritic patients slow the progression of their disease or
even halt it. To test this theory, researchers at Harvard Medical
School supplemented the diets of arthritic patients with a type
of purified Collagen Type II for 3 months. What this study seemed
to indicate is that Collagen supplementation significantly reduced
swelling and joint pain. Now, some experts have speculated that
Collagen Type II may also help prevent the degeneration of joints
that occurs with weight-training exercise and have suggested that
supplementing your diet with Collagen Type II may actually allow
you to build healthier joints.
|